These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 19913350)

  • 1. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies.
    Schröder FH; van den Bergh RC; Wolters T; van Leeuwen PJ; Bangma CH; van der Kwast TH; Roobol MJ
    Eur Urol; 2010 Feb; 57(2):256-66. PubMed ID: 19913350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
    Roobol MJ; van der Cruijsen IW; Schröder FH
    Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening: should more biopsies be taken in larger prostates?
    van Leeuwen P; van den Bergh R; Wolters T; Schröder F; Roobol M
    BJU Int; 2009 Oct; 104(7):919-24. PubMed ID: 19466943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men.
    Postma R; Schröder FH; van der Kwast TH
    Urology; 2005 Apr; 65(4):745-9. PubMed ID: 15833520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
    Roobol MJ; Zhu X; Schröder FH; van Leenders GJ; van Schaik RH; Bangma CH; Steyerberg EW
    Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam.
    de Vries SH; Postma R; Raaijmakers R; Roemeling S; Otto S; de Koning HJ; Schröder FH
    Eur Urol; 2007 Feb; 51(2):366-74; discussion 374. PubMed ID: 16930812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience.
    Van der Kwast TH; Postma R; Hoedemaeker RF; van Leenders GJ; Schröder FH
    Can J Urol; 2005 Jun; 12 Suppl 2():16-20. PubMed ID: 16018827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy.
    Scattoni V; Raber M; Abdollah F; Roscigno M; Dehò F; Angiolilli D; Maccagnano C; Gallina A; Capitanio U; Freschi M; Doglioni C; Rigatti P; Montorsi F
    Eur Urol; 2010 Jan; 57(1):1-8. PubMed ID: 19720449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: results of the prospective European Prostate Cancer Detection study.
    Djavan B; Mazal P; Zlotta A; Wammack R; Ravery V; Remzi M; Susani M; Borkowski A; Hruby S; Boccon-Gibod L; Schulman CC; Marberger M
    Prostate; 2001 May; 47(2):111-7. PubMed ID: 11340633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate biopsy: who, how and when. An update.
    Djavan B; Milani S; Remzi M
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
    Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
    Postma R; Schröder FH; van Leenders GJ; Hoedemaeker RF; Vis AN; Roobol MJ; van der Kwast TH
    Eur Urol; 2007 Jul; 52(1):89-97. PubMed ID: 17257742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
    Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
    Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
    J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam.
    van der Cruijsen-Koeter IW; Roobol MJ; Wildhagen MF; van der Kwast TH; Kirkels WJ; Schröder FH
    Urology; 2006 Sep; 68(3):615-20. PubMed ID: 17010732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?
    Zapatero A; Mínguez R; Nieto S; Martín de Vidales C; García-Vicente F
    Eur Urol; 2009 Apr; 55(4):902-9. PubMed ID: 18485578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.